跳转至内容
Merck
CN

Y0000475

Carboprost trometamol

European Pharmacopoeia (EP) Reference Standard

别名:

(5Z,9α,11α,13E,15S)-9,11,15-Trihydroxy-15- methylprosta-5,13-dien-1-oic acid with 2-amino-2-(hydroxymethyl)-1,3-propanediol (1:1), Carboprost tromethamine

登录查看公司和协议定价


About This Item

经验公式(希尔记法):
C25H47NO8
CAS号:
分子量:
489.64
MDL编号:
UNSPSC代码:
41116107
NACRES:
NA.24

等级

pharmaceutical primary standard

API类

carboprost

制造商/商品名称

EDQM

应用

pharmaceutical (small molecule)

包装形式

neat

储存温度

−20°C

SMILES字符串

NC(CO)(CO)CO.O[C@H]1[C@H](C([C@H](C1)O)\C=C/[C@@](O)(CCCCC)C)C\C=C\CCCC(=O)O

InChI

1S/C21H36O5.C4H11NO3/c1-3-4-9-13-21(2,26)14-12-17-16(18(22)15-19(17)23)10-7-5-6-8-11-20(24)25;5-4(1-6,2-7)3-8/h5,7,12,14,16-19,22-23,26H,3-4,6,8-11,13,15H2,1-2H3,(H,24,25);6-8H,1-3,5H2/b7-5+,14-12-;/t16-,17?,18+,19-,21-;/m0./s1

InChI key

UMMADZJLZAPZAW-QFXCEMDRSA-N

正在寻找类似产品? 访问 产品对比指南

一般描述

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.

应用

Carboprost trometamol EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

包装

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

其他说明

Sales restrictions may apply.

法规信息

监管及禁止进口产品

历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our 文件 section.

如需帮助,请联系 客户支持

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

L A Levine et al.
Cancer, 66(2), 242-245 (1990-07-15)
The treatment of cyclophosphamide-induced hemorrhagic cystitis has been difficult, with overall poor results using intensive and costly therapy. The authors evaluated the treatment of this problem in four patients with prostaglandin intravesical therapy. Each patient had failed to respond to
H Abdel-Aleem et al.
International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics, 42(3), 247-250 (1993-09-01)
To compare carboprost trometamol with methylergometrine in managing the third stage of labor. One hundred and fifty parturient women were randomly assigned to use carboprost trometamol or methylergometrine immediately after delivery. Both the duration of the third stage and the
L A Levine et al.
The Journal of urology, 149(4), 719-723 (1993-04-01)
We review our experience with 18 consecutive patients who received intravesical carboprost tromethamine, an F2-alpha prostaglandin, for severe hemorrhagic cystitis following cyclophosphamide chemotherapy. Of the patients 16 were given cyclophosphamide for conditioning before bone marrow transplantation and 2 received the
Postpartum hemorrhage: new management options.
Gary A Dildy
Clinical obstetrics and gynecology, 45(2), 330-344 (2002-06-06)
D M Kranc et al.
The Journal of urology, 148(4), 1326-1330 (1992-10-01)
Recently, prostaglandins have been shown to be effective agents for the treatment of cyclophosphamide-induced hemorrhagic cystitis. Among the prostaglandins studied is carboprost tromethamine, a PGF2a analog. To determine the effectiveness of carboprost tromethamine therapy on the urothelium, we induced hemorrhagic

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门